Related Experiment Video

Updated: Apr 1, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.9K

Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease

Sourabh Chand1, Nicola C Edwards2, Colin D Chue2

  • 1Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK Centre for Translational Inflammation Research, University of Birmingham, Birmingham, UK.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|October 4, 2015
PubMed

Insights

The caveolin-1 (CAV1) rs4730751 single-nucleotide polymorphism (SNP) CC genotype is linked to reduced arterial stiffness in chronic kidney disease (CKD) patients. This finding suggests CAV1 SNP may serve as a genetic biomarker for arteriosclerosis in CKD.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Genetics

Background:

  • Arteriosclerosis significantly increases cardiovascular mortality risk in chronic kidney disease (CKD) patients.
  • Histological changes in arteriosclerosis include arterial media wall hypertrophy and fibrosis, leading to increased arterial stiffness and end-organ damage.
  • Caveolin-1 (CAV1) plays a role as an intracellular signaling pathway chaperone in fibrotic and vascular diseases.

Purpose of the Study:

  • To investigate the association between the caveolin-1 (CAV1) single-nucleotide polymorphism (SNP) rs4730751 and arterial stiffness.
  • To measure arterial stiffness using arterial pulse wave velocity (PWV) in early-stage and advanced-stage CKD cohorts.

Main Methods:

  • Two non-dialysis CKD cohorts (CRIB and RIISC) were studied, comprising 144 and 147 patients, respectively.
  • Arterial pulse wave velocity (PWV), anthropomorphic, and biochemical data were collected at cohort entry.
  • Genotyping for the CAV1 rs4730751 SNP was performed using Taqman technology.

Main Results:

  • The CAV1 rs4730751 SNP CC genotype was significantly associated with lower arterial PWV in both early-stage CKD (8.1 vs. 8.6 m/s) and advanced-stage CKD (8.7 vs. 9.4 m/s) patients.
  • These associations remained significant after adjusting for other important confounders.
  • The observed relationships were replicated across both study cohorts.

Conclusions:

  • The study suggests that the CAV1 rs4730751 SNP may have utility as a genetic biomarker in CKD.
  • Findings indicate a potential role for CAV1 in the development of arteriosclerosis within the CKD population.
  • Further research is warranted to elucidate the underlying basic science mechanisms.
Abstract

Keywords:
arterial stiffnesscaveolin-1chronic kidney diseasepulse wave velocitysingle-nucleotide polymorphism

More Related Videos

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

20.6K
Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy10:35

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy

Published on: October 19, 2016

11.4K

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
960
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K
Renal Corpuscle01:20

Renal Corpuscle

The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
9.1K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
629